Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles

Lipids Health Dis. 2021 May 6;20(1):48. doi: 10.1186/s12944-021-01475-z.

Abstract

Background: Numerous studies have revealed the relationship between lipid expression and increased cardiovascular risk in ST-segment elevation myocardial infarction (STEMI) patients. Nevertheless, few investigations have focused on the risk stratification of STEMI patients using machine learning algorithms.

Methods: A total of 1355 STEMI patients who underwent percutaneous coronary intervention were enrolled in this study during 2015-2018. Unsupervised machine learning (consensus clustering) was applied to the present cohort to classify patients into different lipid expression phenogroups, without the guidance of clinical outcomes. Kaplan-Meier curves were implemented to show prognosis during a 904-day median follow-up (interquartile range: 587-1316). In the adjusted Cox model, the association of cluster membership with all adverse events including all-cause mortality, all-cause rehospitalization, and cardiac rehospitalization was evaluated.

Results: All patients were classified into three phenogroups, 1, 2, and 3. Patients in phenogroup 1 with the highest Lp(a) and the lowest HDL-C and apoA1 were recognized as the statin-modified cardiovascular risk group. Patients in phenogroup 2 had the highest HDL-C and apoA1 and the lowest TG, TC, LDL-C and apoB. Conversely, patients in phenogroup 3 had the highest TG, TC, LDL-C and apoB and the lowest Lp(a). Additionally, phenogroup 1 had the worst prognosis. Furthermore, a multivariate Cox analysis revealed that patients in phenogroup 1 were at significantly higher risk for all adverse outcomes.

Conclusion: Machine learning-based cluster analysis indicated that STEMI patients with increased concentrations of Lp(a) and decreased concentrations of HDL-C and apoA1 are likely to have adverse clinical outcomes due to statin-modified cardiovascular risks.

Trial registration: ChiCTR1900028516 ( http://www.chictr.org.cn/index.aspx ).

Keywords: Cardiovascular statin-modified risk; Lipoprotein; Machine learning; Prognosis; ST-segment elevation myocardial infarction.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Apolipoprotein A-I / blood*
  • Apolipoprotein B-100 / blood
  • Cholesterol, HDL / blood*
  • Cholesterol, LDL / blood
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lipid Metabolism
  • Lipoprotein(a) / blood*
  • Male
  • Middle Aged
  • Patient Readmission / statistics & numerical data
  • Patient Selection
  • Percutaneous Coronary Intervention
  • Principal Component Analysis
  • Prognosis
  • Risk Assessment
  • ST Elevation Myocardial Infarction / blood*
  • ST Elevation Myocardial Infarction / classification
  • ST Elevation Myocardial Infarction / diagnosis
  • ST Elevation Myocardial Infarction / mortality
  • Triglycerides / blood
  • Unsupervised Machine Learning*

Substances

  • APOA1 protein, human
  • APOB protein, human
  • Apolipoprotein A-I
  • Apolipoprotein B-100
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Lipoprotein(a)
  • Triglycerides